MedCity News

JANUARY 5, 2025

Healthcare experts should be on the lookout for trends related to digital health, prescription drug costs and healthcare coverage in 2025, according to LRVHealth. The post 5 Healthcare Predictions for 2025 from One VC Firm appeared first on MedCity News.

Healthcare 85

Healthcare Healthcare Prescription 85

Pharmaceutical Technology

JANUARY 5, 2025

LR-19155 is under clinical development by LG Chem and currently in Phase I for Non-Small Cell Lung Cancer.

40

40

MedCity News

JANUARY 5, 2025

The Affordable Care Act’s enhanced subsidies are at risk of expiring at the end of 2025, and healthcare leaders are worried about what could happen if Congress doesnt renew them. For instance, more Americans would become uninsured, premiums would increase, and hospitals would be saddled with more bad debt due to uncompensated care. The post The High Stakes of ACA Subsidies: Whats at Risk for Hospitals and Patients appeared first on MedCity News.

Patients 97

Patients Healthcare Healthcare 97

Pharmaceutical Technology

JANUARY 5, 2025

Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Cervical Cancer.

Medicine 40

Medicine 40

Advertiser: ZoomInfo

Incorporating generative AI (gen AI) into your sales process can speed up your wins through improved efficiency, personalized customer interactions, and better informed decision- making. Gen AI is a game changer for busy salespeople and can reduce time-consuming tasks, such as customer research, note-taking, and writing emails, and provide insightful data analysis and recommendations.

Sales

Pharmacy Times

JANUARY 5, 2025

Fiber-rich foods show improvements in health and reductions in chronic diseases, including obesity, by promoting weight management and enhancing the metabolism.

Food 35

Food Leads Pharmaceutical Management 35

Pharmaceutical Technology

JANUARY 5, 2025

GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase I for Rheumatoid Arthritis.

40

40

Pharmaceutical Technology

JANUARY 5, 2025

HLC-001 is under clinical development by Human Life CORD Japan and currently in Phase I for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome.

40

40

MedCity News

JANUARY 5, 2025

The impact of private equity investments in healthcare under the new administration is multifaceted. While deregulation and business-friendly policies could stimulate investment and drive innovation, there are significant concerns about the potential negative effects on healthcare quality and access. The post Will A Second Trump Term be a Financing Boon for Healthcare?

Healthcare 88

Healthcare Healthcare Insurance Physicians 88

Pharmaceutical Technology

JANUARY 5, 2025

CD19-CD22 CAR-T cells is under clinical development by Shanghai Biomed-Union Biotechnology and currently in Phase II for Unspecified B-Cell Lymphomas.

40

40

Pharmaceutical Technology

JANUARY 5, 2025

NMDA Regulator is under clinical development by Boehringer Ingelheim International and currently in Phase I for Unspecified Central Nervous System Disorders.

40

40

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

Pharmaceutical Technology

JANUARY 5, 2025

Paclitaxel is under clinical development by InnoUp Farma and currently in Phase I for Solid Tumor.

40

40

Pharmaceutical Technology

JANUARY 5, 2025

Fosigotifator is under clinical development by Calico Life Sciences and currently in Phase II for Unspecified Central Nervous System Disorders.

40

40

Pharmaceutical Technology

JANUARY 5, 2025

Coronavirus Disease 2019 (COVID-19) vaccine is under clinical development by China National Biotec Group and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Pneumonia.

40

40

Pharmaceutical Technology

JANUARY 5, 2025

BNT-325 is under clinical development by BioNTech and currently in Phase II for Malignant Mesothelioma.

40

40

Advertiser: ZoomInfo

In today’s ultra-competitive markets, it’s no longer enough to wait for buyers to show obvious signs of interest. Instead, sales teams must be proactive, identifying and acting on nuanced buyer behaviors — often before prospects are fully ready to make a purchase. In this eBook from ZoomInfo & Sell Better, learn 10 actionable ways to use these buyer signals to transform your sales strategy and close deals faster.

Sales Strategy

Pharmaceutical Technology

JANUARY 5, 2025

RG-6315 is under clinical development by Genentech USA and currently in Phase I for Systemic Sclerosis (Scleroderma).

40

40

Pharmaceutical Technology

JANUARY 5, 2025

SMART-101 is under clinical development by Smart Immune and currently in Phase II for Refractory Acute Myeloid Leukemia.

40

40

Pharmaceutical Technology

JANUARY 5, 2025

SMART-101 is under clinical development by Smart Immune and currently in Phase II for Relapsed Acute Myeloid Leukemia.

40

40

Pharmaceutical Technology

JANUARY 5, 2025

AKS-452 is under clinical development by Vakston and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

40

40

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

Pharmaceutical Technology

JANUARY 5, 2025

SY-001 is under clinical development by CellOrigin Technology (Hangzhou) and currently in Phase I for Pancreatic Cancer.

40

40

Pharmaceutical Technology

JANUARY 5, 2025

(Ensifentrine + glycopyrrolate) is under clinical development by Verona Pharma and currently in Phase II for Chronic Obstructive Pulmonary Disease (COPD).

Pharma 40

Pharma 40

Pharmaceutical Technology

JANUARY 5, 2025

LY-4052031 is under clinical development by Eli Lilly and Co and currently in Phase I for Ovarian Cancer.

40

40

Pharmaceutical Technology

JANUARY 5, 2025

LY-4052031 is under clinical development by Eli Lilly and Co and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).

40

40

Advertiser: ZoomInfo

As prospects define their problem, search for solutions, and even change jobs, they are generating high-value signals that the best go-to-market teams can leverage to close more deals. This is where signal-based selling comes into play. ZoomInfo CEO Henry Schuck recently broke down specific ways to put four key buying signals into action with the experts from 30 Minutes to President’s Club.

Prospecting

Pharmaceutical Technology

JANUARY 5, 2025

GM-103 is under clinical development by Genemedicine and currently in Phase II for Metastatic Colorectal Cancer.

40

40

Pharmaceutical Technology

JANUARY 5, 2025

SB-207 is under clinical development by Pelthos Therapeutics and currently in Phase II for Genital Warts (Condylomata Acuminata).

40

40

Pharmaceutical Technology

JANUARY 5, 2025

RG-6315 is under clinical development by Genentech USA and currently in Phase I for Systemic Sclerosis (Scleroderma).

40

40

Pharmaceutical Technology

JANUARY 5, 2025

SMART-101 is under clinical development by Smart Immune and currently in Phase II for Refractory Acute Myeloid Leukemia.

40

40

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

Pharmaceutical Technology

JANUARY 5, 2025

SMART-101 is under clinical development by Smart Immune and currently in Phase II for Relapsed Acute Myeloid Leukemia.

40

40

Pharmaceutical Technology

JANUARY 5, 2025

AKS-452 is under clinical development by Vakston and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

40

40

Pharmaceutical Technology

JANUARY 5, 2025

SY-001 is under clinical development by CellOrigin Technology (Hangzhou) and currently in Phase I for Pancreatic Cancer.

40

40

Pharmaceutical Technology

JANUARY 5, 2025

(Ensifentrine + glycopyrrolate) is under clinical development by Verona Pharma and currently in Phase II for Chronic Obstructive Pulmonary Disease (COPD).

Pharma 40

Pharma 40

Advertiser: ZoomInfo

Sales and marketing leaders have reached a tipping point when it comes to using intent data — and they’re not looking back. More than half of all B2B marketers are already using intent data to increase sales, and Gartner predicts this figure will grow to 70 percent. The reason is clear: intent can provide you with massive amounts of data that reveal sales opportunities earlier than ever before.

Sales